Abstract:FKBP51 is well-known as a cochaperone of Hsp90 machinery and implicated in many human diseases including stress-related diseases, tau-mediated neurodegeneration and cancers, which makes FKBP51 an attractive drug target for the therapy of FKBP51-associated diseases. However, it has been reported that only nature product rapamycin, cyclosporine A, FK506 and its derivatives exhibit good binding affinities when bound to FKBP51 by now. Given the advantages of peptide-inhibitors, we designed and obtained 20 peptide-inhibitor hits through structure-based drug design. We further characterized the interaction modes of the peptide-inhibitor hits on the FK1 domain of FKBP51 by biochemical and structural biology methods. Structural analysis revealed that peptide-inhibitor hits form U-shaped conformations and occupy the FK506 binding pocket and share similar interaction modes with FK506. Using molecular dynamics simulations, we delved into the interaction dynamics and found that hits are anchored to the FK506 binding pocket in a quite stable conformation. Meanwhile, it was shown that interactions between FK1 and peptide-inhibitor hits are mainly attributed to the hydrogen bond networks comprising I87 and Y113 and FPF cores of peptide-inhibitors involved extensive hydrophobic interactions. We presumed that the peptide design strategy based on the small molecule structure probably shed new lights on the peptide-inhibitor discovery of other targets. The findings presented here could also serve as a structural basis and starting point facilitating the optimization and generation of FKBP51 peptide-inhibitors with better bio-activities.Peptide-inhibitor hits were designed with small molecules published before used as the starting point through structure-based drug design and biochemically andstructurally characterized the interaction modes between the FK1 domain of FKBP51 and hitsDownload : Download high-res image (86KB)Download : Download full-size image

Drug Discovery Based on the Structure of FKBPs: Design, Synthesis and Evaluation of L-1, 4-Thiazane-3-carboxylic Acid Derivatives As Neuroimmunophilin Ligands

Drug Discovery Based on the Structure of FKBP12: Design, Synthesis and Evaluation of L -1,4-thiazane-3-carboxylic Acid Derivatives As Neuroimmunophilin Ligands

FK506-binding protein ligands: structure-based design, synthesis, and neurotrophic/neuroprotective properties of substituted 5,5-dimethyl-2-(4-thiazolidine)carboxylates.

Design and structure-based study of new potential FKBP12 inhibitors.

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Synthesis and Neuroprotective Biological Evaluation of Quinazolinone Derivatives Via Scaffold Hopping.

Modeling and Synthesis of Non-Cyclic Derivatives of GPI-1046 As Potential FKBP Ligands with Neurotrophic Properties

Discovery of pentapeptide-inhibitor hits targeting FKBP51 by combining computational modeling and X-ray crystallography

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

Design, synthesis, docking, molecular dynamics and bioevaluation studies on novel N-methylpicolinamide and thienopyrimidine derivatives with inhibiting NF-κB and TAK1 activities: Cheminformatics tools RDKit applied in drug design

Structure‐Based Design of Ultrapotent Tricyclic Ligands for FK506‐Binding proteins

Establishment of A Cell Model Based on Fkbp12 Dimerization for Screening of Fk506-Like Neurotrophic Small Molecular Compounds

Binding Modes and Conformational Changes of FK506-binding Protein 51 Induced by Inhibitor Bindings: Insight into Molecular Mechanisms Based on Multiple Simulation Technologies

FK506-binding protein 12 ligands: a patent review.

Discovery of lupus nephritis targeted inhibitors based on De novo molecular design: comprehensive application of vinardo scoring, ADMET analysis, and molecular dynamics simulation

Design, Synthesis, Immunocytochemistry Evaluation, and Molecular Docking Investigation of Several 4-Aminopyridine Derivatives As Potential Neuroprotective Agents for Treating Parkinson'S Disease

Structure-guided design, synthesis, and characterization of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi

Structure-based Design and Confirmation of Peptide Ligands for Neuronal Polo-Like Kinase to Promote Neuroregeneration

Synthesis, Biological Evaluation and Molecular Docking Studies of Novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone Derivatives

Molecular Docking, Synthesis, and Characterization of Furanyl‐pyrazolyl acetamide and 2,4‐thiazolidinyl‐furan‐3‐carboxamide Derivatives as Neuroinflammatory Protective Agents